A Semiautomated Method for Quantification of F 18 Florbetapir PET Images
暂无分享,去创建一个
Mark A. Mintun | Michael D. Devous | Abhinay D. Joshi | M. Mintun | A. Joshi | M. Pontecorvo | D. Skovronsky | M. Devous | Michael J. Pontecorvo | Ming Lu | Daniel M. Skovronsky | M. Lu | A. Joshi
[1] Ralph Myers,et al. Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates , 1999, NeuroImage.
[2] M. Viitanen,et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease , 2006, Neurology.
[3] Karl J. Friston,et al. Statistical parametric mapping , 2013 .
[4] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[5] J L Lancaster,et al. Automated Talairach Atlas labels for functional brain mapping , 2000, Human brain mapping.
[6] Stephen M Smith,et al. Fast robust automated brain extraction , 2002, Human brain mapping.
[7] R. Coleman,et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.
[8] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[9] M. Mintun,et al. Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.
[10] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.
[11] Michael J. Martinez,et al. Bias between MNI and Talairach coordinates analyzed using the ICBM‐152 brain template , 2007, Human brain mapping.
[12] C. Clark,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.
[13] Alan C. Evans,et al. Anatomical mapping of functional activation in stereotactic coordinate space , 1992, NeuroImage.
[14] J C Mazziotta,et al. Automated labeling of the human brain: A preliminary report on the development and evaluation of a forward‐transform method , 1997, Human brain mapping.
[15] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.
[16] James Robert Brašić,et al. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.
[17] Andrea Bergmann,et al. Statistical Parametric Mapping The Analysis Of Functional Brain Images , 2016 .
[18] M. Mintun,et al. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.
[19] W. Klunk,et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. , 2001, Life sciences.
[20] R. Coleman,et al. Use of Florbetapir-PET for Imaging-Amyloid Pathology , 2011 .
[21] R. Mohs,et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.
[22] John Seibyl,et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.
[23] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] C. Rorden,et al. Stereotaxic display of brain lesions. , 2000, Behavioural neurology.
[25] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[26] Paul Edison,et al. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET , 2013, NeuroImage.